Literature DB >> 12160999

Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells.

R X Song1, R J Santen, R Kumar, L Adam, M-H Jeng, S Masamura, W Yue.   

Abstract

Clinical observations suggest that human breast tumors can adapt in response to endocrine therapy by developing hypersensitivity to estradiol. To understand the mechanisms responsible, we examined estrogenic stimulation of cell proliferation in a model system and provided evidence that long-term deprivation of estradiol causes adaptive hypersensitivity. The enhanced responses to estradiol do not involve mechanisms acting at the level of transcription of estrogen regulated genes. We found no evidence of hypersensitivity when examining the effects of estradiol on regulation of c-myc, pS2, progesterone receptor, several ER reporter genes or c-myb in hypersensitive cells. On the other hand, deprivation of breast cells long term was found to up-regulate a separate pathway whereby the estrogen receptor co-opts a classical growth factor pathway and induces rapid non-genomic effects. Through this pathway, estradiol caused rapid activation of mitogen-activated protein (MAP) kinase. In exploring the mechanisms mediating this event, we found that estradiol binds to cell membrane associated estrogen receptors and causes phosphorylation of Shc, an adaptor protein usually involved in growth factor signaling pathways. ERalpha was found to complex with Shc under these conditions. In turn, Shc bound Grb-2 and Sos which resulted in the activation of MAP kinase. The pure antiestrogen, ICI 182,780, blocked several steps in the rapidly responding ER alpha, Shc, MAP kinase pathway. These non-genomic effects of estradiol produced biologic effects by activating Elk and by inducing morphologic changes in cell membranes. Using confocal microscopy, we demonstrated that estradiol caused a rapid alteration in membrane ruffling, the formation of pseudopodia and translocation of ER alpha to regions contiguous with the cell membrane. These morphologic effects could be blocked with a pure anti-estrogen. We conclude that long-term estradiol deprived cells utilize both genomic (transcriptional) and rapid, non-genomic estradiol induced pathways. We postulate that synergy between these two pathways acting at the level of the cell cycle is responsible for adaptive hypersensitivity. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160999     DOI: 10.1016/s0303-7207(02)00093-x

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  12 in total

1.  COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.

Authors:  Bin Su; Xiaohan Cai; Yanyan Hong; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2010-06-11       Impact factor: 4.292

Review 2.  Epigenomic reprogramming of the developing reproductive tract and disease susceptibility in adulthood.

Authors:  Cheryl Lyn Walker
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-06-07

3.  Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.

Authors:  Yukun Cui; Irma Parra; Mao Zhang; Susan G Hilsenbeck; Anna Tsimelzon; Toru Furukawa; Akira Horii; Zhong-Yin Zhang; Robert I Nicholson; Suzanne A W Fuqua
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

Review 4.  Proteins of multiple classes may participate in nongenomic steroid actions.

Authors:  Cheryl S Watson; Bahiru Gametchu
Journal:  Exp Biol Med (Maywood)       Date:  2003-12

Review 5.  Tracking progesterone receptor-mediated actions in breast cancer.

Authors:  Todd P Knutson; Carol A Lange
Journal:  Pharmacol Ther       Date:  2013-11-26       Impact factor: 12.310

6.  Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.

Authors:  Bin Su; Shiuan Chen
Journal:  Bioorg Med Chem Lett       Date:  2009-10-03       Impact factor: 2.823

7.  Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.

Authors:  Luca Magnani; Alexander Stoeck; Xiaoyang Zhang; András Lánczky; Anne C Mirabella; Tian-Li Wang; Balázs Gyorffy; Mathieu Lupien
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

8.  Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.

Authors:  M Hauglid Flågeng; L L Haugan Moi; J M Dixon; J Geisler; E A Lien; W R Miller; P E Lønning; G Mellgren
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

9.  Extracellular alkaline pH leads to increased metastatic potential of estrogen receptor silenced endocrine resistant breast cancer cells.

Authors:  Maitham A Khajah; Iman Almohri; Princy M Mathew; Yunus A Luqmani
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

10.  Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.

Authors:  Joseph A Ludwig; Salah-Eddine Lamhamedi-Cherradi; Ho-Young Lee; Aung Naing; Robert Benjamin
Journal:  Cancers (Basel)       Date:  2011-07-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.